INVO Fertility Q2 Revenue Rises 17% as Clinic-Level Profitability Improves
INVO Fertility (NASDAQ:IVF) reported Q2 2026 revenue up 17% to $2.18 million, with clinic revenue up 18% to $2.17 million. Clinic-level Adjusted EBITDA rose to about $333,000 from $164,000 in Q1, while consolidated Adjusted EBITDA stayed negative at $1.0 million. Cash was $3.7 million.
How this was made
The 30-second read
Why it matters
Q2 results sharpen the profitability split between clinic operations and corporate-level costs. The key trading question is whether additional clinic growth and acquisitions can absorb overhead and move consolidated Adjusted EBITDA toward profitability.
Market read
Traders can reassess the near-term earnings trajectory based on the clinic-level margin improvement versus the ongoing consolidated profitability gap and acquisition integration costs.
What to watch
The net income figure is influenced by a remeasurement gain tied to the Birmingham acquisition, so investors may want to focus more on cash flow and recurring consolidated operating trends than headline net income.
Background
INVO Fertility is expanding its fertility services platform via acquisitions (Family Beginnings) and converting the Birmingham clinic to wholly owned control.
Ticker impact
INVO Fertility reported Q2 2026 revenue up 17% to $2.18M and clinic-level Adjusted EBITDA rising to about $333K from $164K.
Near-term bias modestly positive on the clinic-level margin improvement, but upside may be capped until consolidated profitability trends toward breakeven.
The article provides fresh quarterly financial datapoints (revenue, clinic EBITDA, consolidated EBITDA, cash) and highlights the corporate cost drag, which typically drives investor debate on whether scale can close the gap.
Market effects
Highlights a common fertility-clinic model issue: clinic-level profitability can improve while corporate overhead and acquisition integration keep consolidated results negative.
No specific regional read-through beyond U.S. clinic acquisition and organic growth mentions.
Limited, as the disclosure is company-specific and not a sector-wide regulatory or macro catalyst.
Counterpoint
Clinic-level EBITDA improvement may not translate to consolidated profitability if corporate costs rise with acquisition-driven scale or integration expenses persist.
Key entities
- companyINVO Fertility
Reported Q2 2026 revenue growth, clinic-level Adjusted EBITDA improvement, and still-negative consolidated Adjusted EBITDA, plus cash increase and acquisition-related accounting impacts.
- acquired businessFamily Beginnings
Indiana-based acquisition cited as the first full-quarter contribution driving Q2 revenue growth.
- operating assetBirmingham, Alabama fertility clinic
Conversion to wholly owned subsidiary and related remeasurement gain referenced in the quarter’s net income.
